Preclinical risk assessment services
Our Cambridge facility is located 50 miles north of London in the UK.
The Cambridge site has relocated to larger premises and now houses multiple modern preclinical research laboratories with a wide range of high throughput screening equipment.
Our Early Development Services team focuses on a full risk assessment platform for in silico and in vitro services for developability, immunogenicity, stability, antibody humanization, protein engineering and non-GMP mammalian and microbial expression. These services utilize our award winning and patented Epibase® T cell epitope screening platform along with our proprietary platforms for protein risk assessment and engineering and Lonza’s proprietary expression platforms.
Whether you are looking for non-GMP immunogenicity in the case of protein therapeutics, or a strong response to a developing vaccine, our protein experts can help optimize your drug candidate to give you the best chance for clinical success.